The U.S. Food and Drug Administration (FDA) has issued a safety communication alert about the potential for batteries of certain Medtronic implantable pacemakers to drain more quickly than expected and without warning to patients. At this time, preventative removal and replacement of affected devices is not recommended. Rather, patients and professionals should carefully monitor battery status using home monitoring systems.

The FDA will continue to work with Medtronic to monitor affected pacemakers and cardiac resynchronization therapy pacemakers for any adverse events related to premature battery depletion, and will keep the public informed as new information becomes available.

Read more on FDA's website.

Clinical Topics: Arrhythmias and Clinical EP, Cardiovascular Care Team, Heart Failure and Cardiomyopathies, Implantable Devices, SCD/Ventricular Arrhythmias, Atrial Fibrillation/Supraventricular Arrhythmias

Keywords: ACC Advocacy, Cardiac Resynchronization Therapy, United States Food and Drug Administration, Monitoring, Physiologic, Arrhythmias, Cardiac, Pacemaker, Artificial, Defibrillators, Implantable

< Back to Listings